scPharmaceuticals Inc.
SCPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | -0.48 | -0.20 | 0.22 |
| FCF Yield | -44.77% | -24.55% | -17.02% | -19.78% |
| EV / EBITDA | -1.74 | -5.10 | -5.13 | -3.22 |
| Quality | ||||
| ROIC | -69.56% | -67.81% | -30.66% | -34.67% |
| Gross Margin | 68.73% | 71.96% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.83 | 1.08 | 0.94 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -19.02% | -71.35% | -27.39% | 1.92% |
| Safety | ||||
| Net Debt / EBITDA | 0.30 | 0.14 | 1.02 | 2.26 |
| Interest Coverage | -8.56 | -6.82 | -10.95 | -10.03 |
| Efficiency | ||||
| Inventory Turnover | 0.82 | 0.43 | 0.38 | 0.00 |
| Cash Conversion Cycle | 439.67 | 584.00 | -224.62 | -453.33 |